, Columnist
Biotech Shouldn't Sweat the Election So Much
A Clinton presidency may not have a big impact on drug pricing.
This article is for subscribers only.
The U.S. presidential election has made everything feel radioactive; biotech stocks are no exception.
A single Hillary Clinton tweet decrying high drug prices sent the Nasdaq Biotech Index (NBI) down 4.7 percent in one day in September 2015. Worry about the potential policy (and drug-pricing) ramifications of a Democratic sweep of the presidency and both houses of Congress has provoked a renewed funk in biotech shares lately.